These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31859459)

  • 1. The pharmacology and therapeutic applications of monoclonal antibodies.
    Castelli MS; McGonigle P; Hornby PJ
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00535. PubMed ID: 31859459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Development of Therapeutic Monoclonal Antibodies.
    Mould DR; Meibohm B
    BioDrugs; 2016 Aug; 30(4):275-93. PubMed ID: 27342605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.
    Shim H
    Exp Mol Med; 2011 Oct; 43(10):539-49. PubMed ID: 21811090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic proteins.
    Dimitrov DS
    Methods Mol Biol; 2012; 899():1-26. PubMed ID: 22735943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
    Tsao LC; Force J; Hartman ZC
    Cancer Res; 2021 Sep; 81(18):4641-4651. PubMed ID: 34145037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
    Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
    Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Antibodies: A Review.
    Singh S; Kumar NK; Dwiwedi P; Charan J; Kaur R; Sidhu P; Chugh VK
    Curr Clin Pharmacol; 2018; 13(2):85-99. PubMed ID: 28799485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.
    Imamura CK
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):14-18. PubMed ID: 30606646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies as therapeutics in human malignancies.
    Pandey M; Mahadevan D
    Future Oncol; 2014 Mar; 10(4):609-36. PubMed ID: 24754592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
    Tshiani Mbaya O; Mukumbayi P; Mulangu S
    Front Immunol; 2021; 12():721328. PubMed ID: 34526994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
    Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
    Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
    MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging trends and therapeutic applications of monoclonal antibodies.
    Mekala JR; Nalluri HP; Reddy PN; S B S; N S SK; G V S D SK; Dhiman R; Chamarthy S; Komaragiri RR; Manyam RR; Dirisala VR
    Gene; 2024 Oct; 925():148607. PubMed ID: 38797505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next generation of antibody-drug conjugates comes of age.
    Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
    Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building better monoclonal antibody-based therapeutics.
    Weiner GJ
    Nat Rev Cancer; 2015 Jun; 15(6):361-70. PubMed ID: 25998715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies].
    Ishii-Watabe A; Tada M; Suzuki T; Kawasaki N
    Yakugaku Zasshi; 2015; 135(7):857-66. PubMed ID: 26135085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
    Mir O; Broutin S; Desnoyer A; Delahousse J; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():103-106. PubMed ID: 32089494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.
    Lynch CM; Hart BW; Grewal IS
    MAbs; 2009; 1(1):2-11. PubMed ID: 20046568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.